Auris Medical Holding AG (NASDAQ: EARS) is having an overwhelmingly strong start to the trading session this morning after announcing that one of its clinical-stage assets was the focus of a report in a peer-reviewed medical journal. Of course, this led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about:
- The publication in the journal;
- what we’re seeing from EARS as a result;
- and what we’ll be watching for ahead.
EARS Heads For The Top On Clinical Publication
As mentioned above, Auris Medical Holding is having an incredibly strong start to the trading session this morning after announcing that a peer reviewed journal published an article featuring its candidate. In a press release issued early this morning, the company announced the publication of an article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111. AM-111 is an investigational treatment for acute inner ear hearing loss being developed by EARS. The peer-reviewed article is titled “Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)”. The article was published in Hearing Research, one of the leading journals in the field of otorhinolaryngology. In a statement, Thomas Meyer, founder, Chairman and CEO at EARS, had the following to offer:
The publication summarizes the extensive body of non-clinical and clinical data on AM-111 that have been accumulating over more than 15 years of research… Numerous studies have demonstrated AM-111’s strong otoprotective effects across various types of acute cochlear injury, ranging from traumatic conditions such as sound overexposure or cochlear implantation to non-traumatic conditions such as acute inflammation, infection, vascular disturbances or ototoxic medications.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. In the case of Auris Medical, the news proved to be overwhelmingly positive. When a peer reviewed journal publishes data revolving around a clinical-phase treatment, what they are really doing is showing their support or lack thereof. Considering that the article was positive, what we learned today was that a highly trusted journal further validated AM-111 as a strong potential option for these patients. So, it’s no surprise to see that the stock is making a run for the top in the market this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:07), EARS is trading at $1.61 per share after a gain of $0.21 per share or 15.00% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on EARS. In particular, we’re interested in following the story surrounding the company’s continued development of AM-111, especially after today’s validation from Hearing Research! Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!